Nancy Harrison

Evolved Therapeutics is focused on establishing innovative antibody discovery platforms to enable the discovery of first- and best-in-class therapeutics.

Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the burgeoning digital health sector through its leadership as investor, partner, and mentor.

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

With offices in Montreal, Vancouver and Toronto, adMare is building Canada’s life science industry from sea to sea. With a strong track record of globally-competitive scientific discovery, Canada is primed to lead the life sciences world. To make this a reality, at adMare BioInnovations, we use our scientific and commercial expertise, specialized R&D infrastructure, and seed capital to build strong life sciences companies, robust ecosystems and industry-ready talent — and re-invest our returns back into the Canadian industry to ensure its long-term sustainability. www.admarebio.com Avec des bureaux situés à Montréal, Vancouver et Toronto, adMare développe le secteur canadien des sciences de la vie d’un océan à l’autre. Grâce à sa riche expérience en matière de découvertes scientifiques concurrentielles à l’échelle internationale, le Canada est prêt à devenir un chef de file mondial dans le domaine des sciences de la vie. C’est pour concrétiser cet objectif qu’adMare BioInnovations tire parti de son expertise technique et commerciale, de son infrastructure de recherche et développement spécialisée et de son capital d’investissement pour développer de solides entreprises des sciences de la vie, des écosystèmes robustes et les talents prêts à travailler dans l’industrie. Nous réinvestissons nos bénéfices dans l’industrie canadienne pour assurer son maintien à long terme. www.admarebio.com/fr

Evolved Therapeutics is focused on establishing innovative antibody discovery platforms to enable the discovery of first- and best-in-class therapeutics.

Nimbus Synergies leads early-stage financings in innovative and complementary health technology companies in Canada. By bringing these companies together to share resources, industry specific knowledge, and relationships, Nimbus is accelerating their growth and increasing their likelihood of success. Nimbus is significantly impacting the burgeoning digital health sector through its leadership as investor, partner, and mentor.

Congruence is a computationally-driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary scalable platform, Revenir™, captures the biophysical features of proteins across their conformational ensembles, in order to identify novel allosteric and cryptic pockets which are virtually screened to generate novel chemical matter.

Abdera Therapeutics Inc. is a precision oncology company developing next-generation targeted radiation therapies - one of the most cutting-edge and highly promising areas of drug development. The company is built on a proprietary modular technology platform optimized for the delivery of radioisotopes to selectively destroy tumor cells while sparing healthy cells. Abdera is using this platform to enable the rapid development of a broad range of safe and efficacious therapies serving cancer patients with limited treatment options. Abdera Therapeutics is growing rapidly and seeking key new team members who thrive at the cutting-edge of innovation. Come join us and be a part of the ground-breaking team set to unlock the power of targeted radiotherapy!

Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with Canadas most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is focused on building world-class Canadian companies in precision medicine and next-generation medical devices. Since 2012, the Amplitude team has deployed a venture growth model used to build Canadian companies with world-class management teams and scale companies to breakout potential. This model has been used by the team to create, build, and grow companies, resulting in over $1 billion in company value. Our offices are in Montreal, Toronto, and Vancouver.